emovis by FutureMeds’ Post

Dear Reader, It brings us immense joy to have you join us on this remarkable journey toward medical progress! 🚀 If you haven't already, kindly click the "Follow" button under the FutureMeds account to stay abreast of the latest news, medical insights, and innovative solutions we are introducing to the field of healthcare. A sincere shoutout to our current followers – your unwavering support is genuinely appreciated! 🙌 Thank you for being an integral part of the our family. Wishing each and every one of you Happy Holidays filled with joy, good health, and cherished moments! 🎄🎁 Let's continue collaboratively shaping the future of medicine. Follow everything we do on FutureMeds :) #FutureMeds #HealthcareInnovation #ChristmasCheers 🌟

🚀 Exciting News! 🚀 Thrilled to share that our brand-new website, www.emovis.de, is now live and ready for your visit! 🌐✨ Explore our latest new features, like our recruitment table and discover our comprehensive service offering. 🌍💡 Join us on this journey by checking out our website today! Your support means the world to us. 🤝🔗 For more updates follow us on FutureMeds

🏡 emovis Homecare Visits: Expanding Possibilities in Clinical Research 🌐 Embracing innovation in clinical trials opens doors to a more inclusive and patient-centric approach. Here's why incorporating homecare visits into your study design could be a game-changer: 1️⃣ **Reach Diverse Patient Populations:**   - Include seriously ill patients with limited mobility.   - Reach those with rare diseases residing far from study centers.   - Accommodate young participants, minimizing travel-related burdens. 2️⃣ **Wider Patient Recruitment:**   - Overcome geographical barriers and tap into a larger pool of eligible participants.   - Ensure that distance doesn't limit the diversity of your study population. 3️⃣ **Enhanced Compliance:**   - Long journeys can deter patient participation.   - Homecare visits promote higher compliance by eliminating travel constraints. 4️⃣ **Patient-Centric Retention:**   - Provide a comprehensive customer service experience.   - Improve retention rates by prioritizing patient comfort and convenience. 5️⃣ **Accessible Studies for All:**   - Conduct studies for conditions where patients face significant mobility challenges.   - Break down barriers to participation for those unable to leave their homes. By leveraging emovis Homecare Visits, we're not just advancing research methodologies but ensuring that every patient, irrespective of their circumstances, can contribute to the progress of medical science. Let's make clinical trials more inclusive and impactful! 🌟 #ClinicalResearch #PatientCentricity Follow us on FutureMeds for more!

The 31st Bundesverband Medizinischer Auftragsinstitute e.V. (BVMA)(BVMA)Symposium in Munich is just around the corner. Representing 46 companies and over 70% of the German CRO market's employees, the BVMA association serves as a vital hub for information, insights and trends in clinical research, enhancing the members' knowledge, opportunities and capabilities. At the upcoming event, FutureMeds Germany will be represented by Iwona Tongbhoyai, Dr. med. Bettina Bergtholdt, Ninon Armbrust a member of the program committee, and Johannes Gass. A key focus for our team will be the "Studienstandort Deutschland" session, which explores the factors behind the decrease in clinical trials in Germany. We aim to gain deeper insights into the trends shaping trial opportunities in the country and discuss the steps the local industry can take to improve the situation. BVMA membership is a badge of honour. It signifies a commitment to high-quality standards due to the rigorous system audits required for membership. We are proud to be members and look forward to the insightful discussions in Munich. Follow us on FutureMeds for more. #BVMA2023 #ClinicalResearch #ClinicalTrials

emovis by FutureMeds Delivers Comprehensive Decentralized Clinical Trial Solutions In the ever-evolving realm of clinical research, patient participation is vital, but obstacles often impede involvement. emovis by FutureMeds pioneers Decentralized Clinical Trial (DCT) services to overcome challenges and transform the clinical research landscape. As a trusted Dedicated Study Site provider, emovis offers a range of services, including the Homecare Visits Service, addressing patient-specific constraints for seamless trial conduct. With a decade of expertise in hybrid DCT services, emovis, through its specialized DCT Task Force, provides virtual study centers, network investigators, digital patient recruitment, inpatient sites, supply and device management, local healthcare providers, and home visits. 🔧 Tailored Solutions for Every Study 🔧 Emovis' DCT solutions serve as a customizable toolkit, ensuring adaptability to each study's unique requirements, whether implemented as a hybrid or fully decentralized solution. 🌍 Regulatory Compliance and Safety Assurance 🌍 The emovis DCT Task Force adheres to regulations from the European Medicines Agency and national authorities, ensuring a meticulous assessment of study needs for efficient and secure decentralization. Join us in reshaping decentralized clinical trials for a more accessible and patient-friendly future and follow us on FutureMeds for more. #ClinicalResearch #DecentralizedTrials #InnovationInHealthcare

While many of you know us as a Dedicated Study Site, we're more than just that. Since our establishment in 2001, we've continuously evolved and developed innovative site and study solutions that have benefited over 100 clients. 🚀 Our mission is to further medical progress and we stand by it. Whatever your project entails, we're ready to embrace any challenge. We're dedicated to developing effective solutions that help you navigate your clinical trials successfully. Why consider adding Emovis by FutureMeds to your location mix? Here are some compelling reasons: 1️⃣ Patient-Centric Approach: All our services are built on direct patient contact, benefiting both researchers and patients. Collaborating with our Principal Investigators and research nurses puts the patient's voice at the forefront, guiding study design. 2️⃣ Vast Experience: Our experienced and dedicated team has conducted over 250 studies spanning 120 indications across 14 therapeutic areas. 3️⃣ Innovation: We're continually seeking more efficient and improved solutions. From pioneering HomeCare visits a decade before the pandemic to developing a comprehensive DCT toolkit, establishing a sleep lab, early phase unit, and a COVID study unit, we're committed to innovation. 4️⃣ Patient Recruitment: Study success heavily relies on recruiting suitable, committed patients. Through close and dedicated patient involvement, we've consistently achieved high recruitment figures over the years. Emovis by FutureMeds, is your partner in redefining the future of clinical trials. Let's collaborate and make the impossible possible. Together, we'll drive groundbreaking research and deliver transformative results. Reach out to us and let's embark on this exciting journey! #ClinicalTrials #DCT #PatientCentric Follow us on FutureMeds for more!

Dr. med. Bettina Bergtholdt, CEO of emovis by FutureMeds, shared her inspiring entrepreneurial journey spanning over two decades with us. Discover the incredible developments at emovis, including the evolution of our Decentralized Clinical Trials (DCT) division in our blog. Here's a short snippet of the interview: Bettina, the founder of emovis, embarked on this journey under an apple tree with a simple question: "Why not start our own company?" She dove into entrepreneurship despite limited resources and no prior business experience. Her commitment paid off as emovis flourished over the years. Today, emovis offers a myriad of services, with a strong focus on DCTs. Bettina predicts a surge in DCTs, benefiting sponsors and patients alike, especially in the EU. Notably, emovis has been acquired by FutureMeds, expanding their DCT services worldwide. While many uncertainties regarding DCTs and legal framework still exist in Europe, DCTs are gaining traction, especially in low-risk indications. The merger with FutureMeds will streamline operations and offer clients a one-stop solution. The future looks promising for emovis by FutureMeds. Join us on this exciting journey of transformation in the clinical trials industry! Read the full interview to learn more and follow us on FutureMeds https://lnkd.in/dYqfFBNc. #ClinicalTrials #DCT #FutureMeds #Innovation.

Join Dr. med. Bettina Bergtholdt at the CMPRR Summit 2023 for an enlightening keynote about the future of virtual studies. 🎤 In her keynote, 𝗔 𝗝𝗼𝘂𝗿𝗻𝗲𝘆 𝗜𝗻𝘁𝗼 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲: 𝗠𝗼𝗱𝘂𝗹𝗲𝘀 𝗳𝗼𝗿 𝗖𝗼𝗻𝗱𝘂𝗰𝘁𝗶𝗻𝗴 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗦𝘁𝘂𝗱𝗶𝗲𝘀, the Managing Director at FutureMeds Germany will talk about - Babylonian language confusion: Understanding the terminology - DCTs, virtual trials, hybrid trials - Virtual study sites: if and how they might become a reality - Essential toolbox: Navigating through necessities from e-signatures to Homecare Services 🗓️ 𝗪𝗵𝗲𝗻? 15th November 2023, 9:15 AM 📍 𝗪𝗵𝗲𝗿𝗲? 9th Annual Monitoring & Patient Recruitment Retention Summit Barcelona, Spain About the CMPRR Summit: Organised by KP-Morgan Group the CMPRR Summit is a unique convergence of like-minded professionals, experienced speakers, and emerging talents who aim to navigate the challenges of clinical operations, project management, and patient engagement. If you’re present at the summit, seize the opportunity to learn how to empower your patients through DCTs in Europe. For more updates follow us on FutureMeds #ClinicalTrials #ClinicalResearch #CMPRR